Kyntra Bio (KYNB) Non-Current Assets (2014 - 2026)
Kyntra Bio (KYNB) posted Non-Current Assets of $8.3 million for Q1 2026, down 59.68% sequentially from $20.5 million in Q4 2025, and down 50.41% YoY from $16.7 million in Q1 2025.
Kyntra Bio (KYNB) Non-Current Assets (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Non-Current Assets for 13 years, with the latest figure at $8.3 million in Q1 2026.
- Quarterly Non-Current Assets fell 50.41% year-over-year to $8.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.1 million (down 65.22% YoY) and the FY2025 annual result came in at $20.5 million, up 13.9% from the prior year.
- Non-Current Assets declined to $8.3 million in Q1 2026 per KYNB's latest filing, from $20.5 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $221.5 million in Q1 2022 and troughed at $3.6 million in Q3 2025.
- A 5-year average of $77.3 million and a median of $87.7 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets soared 33.76% in 2022, then plunged 81.95% in 2025.
- Over 5 years, Non-Current Assets stood at $117.3 million in 2022, then slipped by 21.57% to $92.0 million in 2023, then tumbled by 80.41% to $18.0 million in 2024, then increased by 13.9% to $20.5 million in 2025, then tumbled by 59.68% to $8.3 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $8.3 million, $20.5 million, and $3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | Kyntra Bio | 30.32 Mn | 30.32 Mn | 1.47 Mn | 4.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.25 Mn |
| Mar 31, 2026 | 8.27 Mn |
| Dec 31, 2025 | 20.52 Mn |
| Sep 30, 2025 | 3.59 Mn |
| Jun 30, 2025 | 15.73 Mn |
| Mar 31, 2025 | 16.68 Mn |
| Dec 31, 2024 | 18.02 Mn |
| Sep 30, 2024 | 19.89 Mn |
| Jun 30, 2024 | 83.74 Mn |
| Mar 31, 2024 | 87.70 Mn |
| Dec 31, 2023 | 91.97 Mn |
| Sep 30, 2023 | 96.32 Mn |
| Jun 30, 2023 | 103.77 Mn |
| Mar 31, 2023 | 108.00 Mn |
| Dec 31, 2022 | 117.26 Mn |
| Sep 30, 2022 | 134.61 Mn |
| Jun 30, 2022 | 166.15 Mn |
| Mar 31, 2022 | 221.52 Mn |
| Dec 31, 2021 | 299.76 Mn |
| Sep 30, 2021 | 277.11 Mn |